| InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting International supplier of animal free, productivity enhancing cell culture media components offers its customers the chance to improve performance of cell culture development and bioproduction. Fort Collins, CO. The 2008 Cell Engineering Conference, hosted by the Williamsburg BioProcessing Foundation, featured the products and supporting research data of InVitria [http://www.invitria.com], a company committed to delivering affordable, high-performing cell culture media components for bioproduction and regenerative medicine applications. Over the course of the three day conference in Santa Barbara, CA, InVitria exhibited its Cellastim and Lacromin cell culture media component products to industry leaders seeking ways to improve their development timelines and optimize bioproduction. InVitria's Director of Cell Culture, Dr. Steve Pettit, presented at the meeting and revealed data from a study entitled, "Recombinant Human Serum Albumin Expressed in Plants Improves the Productivity and Growth Kinetics of CHO." Tests have shown that Cellastim outperforms plasma-derived human serum albumin and can result in improved doubling time and an average 50% increase in productivity across a variety of chemically defined cell culture media. "WilBio's Cell Engineering Conference was a great venue for InVitria to learn about the cell line development challenges facing the biopharmaceutical industry," said InVitria President Scott Deeter. "InVitria is dedicated to working with customers to improve cell line development speed by improving doubling time and expediting the development process without the use of serum or other animal components," Deeter said. About InVitria For more information about InVitria's products, please contact us by e-mail or phone. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it Phone: 1-800-916-8311
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
